A federal judge in Massachusetts on Monday blocked Health Secretary Robert F. Kennedy Jr.’s recent overhaul of the nation’s childhood vaccine schedule.
Legal Challenge to Vaccine Changes
The ruling follows a lawsuit brought by the American Academy of Pediatrics and other medical groups against the Department of Health and Human Services. The lawsuit argued that Kennedy’s changes to vaccine recommendations and to an influential vaccine advisory committee violated federal law.
The changes, made in January, reduced the number of recommended shots for children from 18 to 11. The CDC’s revised guidance removed recommendations for universal vaccination against hepatitis A, hepatitis B, RSV, dengue, and two types of bacterial meningitis.
Impact on Advisory Committee
The judge’s order also halts the implementation of new appointments made by Kennedy last June to the CDC’s vaccine advisory committee. This Advisory Committee on Immunization Practices plays a key role in shaping U.S. Vaccine policy, including determining which vaccines are recommended for children and which are covered by insurance.
According to Richard Hughes, an attorney for the AAP, the judge’s decision effectively prevents the advisory committee from holding its scheduled meeting on Wednesday and Thursday.
Frequently Asked Questions
What prompted this lawsuit?
The American Academy of Pediatrics and other medical groups filed suit arguing that Health Secretary Robert F. Kennedy Jr.’s changes to vaccine recommendations and the vaccine advisory committee violated federal law.
What specific vaccines were affected by the changes?
The CDC’s revised guidance dropped recommendations that all babies should be protected against hepatitis A, hepatitis B, RSV, dengue and two types of bacterial meningitis.
What is the role of the Advisory Committee on Immunization Practices?
The Advisory Committee on Immunization Practices helps shape U.S. Vaccine policy, including recommendations that influence the childhood vaccine schedule and which shots must be covered by insurance.
How might this ruling affect future vaccine policy decisions?
Worth a look